BamSEC and AlphaSense Join Forces
Learn More

Protagenic Therapeutics Inc.

NASDAQ: PTIX    
Share price (12/23/24): $0.53    
Market cap (12/23/24): $3.633 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 8-K 23 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 38 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 4 pages Promissory Note
12/34/56
EX-10.15
from S-1/A 23 pages Form of Warrant Agent Agreement
12/34/56
EX-10.15
from S-1/A 23 pages Form of Warrant Agent Agreement
12/34/56
EX-10.15
from S-1/A 23 pages Form of Warrant Agent Agreement
12/34/56
EX-10.4
from 10-K 9 pages Material contract
12/34/56
EX-10.2
from 10-K 9 pages Material contract
12/34/56
EX-10.3
from 8-K 4 pages Form of Guaranty
12/34/56
EX-10.2
from 8-K 9 pages Convertible Promissory Note
12/34/56
EX-10.1
from 8-K 18 pages Convertible Note Purchase Agreement
12/34/56
EX-10.16
from 10-K/A 6 pages Consulting Agreement
12/34/56
EX-10.16
from 10-K 6 pages Consulting Agreement
12/34/56
EX-10.3
from 8-K 7 pages Nonqualified Stock Option Grant Agreement Protagenic Therapeutics, Inc
12/34/56
EX-10.2
from 8-K 7 pages Incentive Stock Option Grant Agreement Protagenic Therapeutics, Inc
12/34/56
EX-10.1
from 8-K 35 pages Protagenic Therapeutics, Inc. 2016 Equity Compensation Plan
12/34/56
EX-10.4
from 8-K 13 pages Escrow Agreement
12/34/56
EX-10.3
from 8-K 26 pages January 25, 2016 Mr. Edward Gildea Chief Executive Officer Atrinsic, Inc. 65 Atlantic Avenue Boston, Ma 02110 Re: Private Placement Offering of Up to $4 Million of Series B Preferred Stock Dear Mr. Gildea
12/34/56
EX-10.2
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 26 pages Securities Purchase Agreement
12/34/56